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Abstract
Background: Mucopolysaccharidosis type VII (Sly disease, MPS VII), is an ultra-rare, multi-symptom disease with
variable clinical presentations which can present challenges with diagnosis, management and care. We believe this
survey is the first to explore the patient experience through direct questioning of the caregivers of 13 individuals
with MPS VII.
Methods: This European survey, using a specifically designed questionnaire, was conducted in order to describe
the pathway to diagnosis and the burden of illness of MPS VII. Information on early symptoms, clinicians seen, and
current symptoms was collected. Questions on the caregivers’ ability to work and the use and availability of health,
social and educational support were included.
Results: Caregivers of 13 patients from Germany, Spain, The Netherlands and Turkey responded to the survey. Five
patients with non-immune hydrops fetalis (NIHF) were diagnosed with MPS VII at a mean age of 1.9 years (median
0.3 years, range 0.2 to 6 years). Those without NIHF (n = 7) were diagnosed at a mean age of 6.1 years (median 6.0
years, range 1.9 to 14 years). The symptoms most likely to raise a suspicion of MPS VII, excluding NIHF, did not
appear until a median age of at least three years.
Over one half of patients required assistance with daily living and mobility. Reduction of the working hours of
caregivers was often necessary (46.2% reduced hours, 30.8% stopped working).
Patients attended frequent medical appointments (12.7/year), over 80% had surgery and 30% had been hospitalised
for respiratory issues.
While support for learning and behavioural needs was generally available, support for mobility was not available to
50% of patients. Half of the respondents (6/12) said they were not offered genetic counselling.
Conclusions: For children that do not present with NIHF, diagnosis can take several years as early symptoms can
be non-specific and mistaken for other conditions. Increased awareness of the early signs of disease and more
information for parents/caregivers at diagnosis are needed. MPS VII poses significant burden to patients, caregivers,
healthcare, social and educational services. Access to information and support varies across Europe and the
availability of genetic counselling is limited in some countries.
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Background
Mucopolysaccharidosis type VII (Sly disease, MPS VII), is
an ultra-rare autosomal recessive, lysosomal storage dis-
order caused by deficiency of the enzyme β-glucuronidase
(GUSB). First described by Sly et al. in 1973, the absence
of GUSB activity leads to the progressive accumulation of
un-degraded glycosaminoglycans (GAGs) in many tissues
of the body [1, 2]. The result is only partial degradation of
the GAGs chondroitin, dermatan and heparan sulfate and
leads to accumulation of these partially degraded frag-
ments in the lysosomes of many tissues and organs, even-
tually leading to cellular and organ dysfunction [1]. In the
United Kingdom, MPS VII is the rarest mucopolysacchari-
dosis with an average of only one affected birth every 10
years [3]. Worldwide it is estimated to have a frequency of
less than 1:1,000,000 births [4].
The extreme rarity of MPS VII means that information
on the natural history and clinical characteristics of the
disease are scarce [5].
Patients can present with short stature, skeletal dyspla-
sia, joint contractures, hepatosplenomegaly, hernias,
cardiac involvement, pulmonary insufficiency, corneal
clouding, hearing impairment and recurrent upper re-
spiratory and middle ear infections [1, 6].
Cognitive, linguistic and social developmental delay is
often present and patients may have behavioural distur-
bances such as hyperactivity, attention difficulties and
extreme frustration [1, 7].
Affected patients can show a wide range of clinical
variability, from early, severe, multisystem manifestations
and progressive intellectual disability to a milder pheno-
type with later onset, fewer clinical manifestations and
normal or near-normal intelligence [1, 6].
In the most severe cases, MPS VII presents as non-
immune hydrops fetalis (NIHF) and may result in stillbirth
or death within the first few weeks of life. However, the
presence of NIHF does not always predict the severity of
disease and does not always result in neonatal death [1].
Life expectancy is generally reduced due to frequent
upper respiratory tract infections, neurodegenerative
complications and abnormalities of the gastrointestinal
tract, although patients with milder disease have sur-
vived into their fifth decade [1, 6].
As is the case with other rare diseases, patients with MPS
VII may experience delays with their diagnosis, are often
misdiagnosed and visit numerous doctors before they re-
ceive their final diagnosis [8]. In the absence of NIHF, MPS
VII may not be suspected until several years after the symp-
toms have appeared. There is very little information on the
evolution of symptoms, how patients are managed and
under which specialty of clinicians prior to diagnosis. When
there is a suspicion of MPS VII, the first step on the diag-
nostic pathway is through measurement of the GAGs der-
matan, heparan and chondroitin sulfate in urine [9, 10].
GAG levels may be near normal in attenuated patients and
therefore a test of enzyme activity in the blood is usually
conducted when MPS VII is suspected [6]. Molecular gen-
etic testing for mutations in the GUSB gene can be used to
confirm the diagnosis [6]. Prenatal diagnosis is possible
through amniocentesis to measure GAGs and GUSB activ-
ity or chorionic villus sampling for enzymatic and genetic
analysis [11–14]. Genetic counselling is recommended for
people with MPS VII and their families [3], yet it is not
known if this is routinely available to all. Patients with MPS
VII have significant and complex health needs. Current
treatment options include haematopoietic stem cell trans-
plantation (HSCT) with bone marrow or umbilical cord
blood stem cells [3]. While experience of HSCT in MPS
VII is limited, improvements in upper airway and respira-
tory function, hearing, vision, cardiac function, hepatosple-
nomegaly and joint mobility have been reported [15] and
results suggest that it can slow or prevent further neuro-
logical complications [1, 15, 16].
Vestronidase alfa has received marketing approval in the
US (2017) [17], Europe (2018) [18] and Brazil (2018) [19]
as the first enzyme replacement therapy (ERT) for the
treatment of non-neurological manifestations of MPS VII.
In a recent Phase III trial, 12 patients with MPS VII were
divided into 1 of 4 blinded groups with each group rando-
mised to receive vestronidase alfa for 24 weeks at different
time points. Treatment resulted in meaningful improve-
ments to at least one of the clinical domains that the
authors tested for that included a 6-min walk test, Forced
Vital Capacity, shoulder flexion, visual acuity, and
Bruininks-Oseretsky Test of Motor Proficiency (BOT-2)
[20]. Symptomatic treatments of MPS VII include physio-
therapy and hydrotherapy to improve activity levels, over-
all health and can help drain the build-up of mucus in the
lungs [3]. Patients need regular clinical follow up and may
require surgery to correct bone deformities, spinal cord
compression, hernias, carpal tunnel syndrome and ocular
and cardiovascular abnormalities [21, 22].
As new treatment options become available, the need
for more information on the natural history and disease
burden of MPS VII, to inform health economic analyses
and health policy decisions on access to treatment be-
comes apparent [23]. Furthermore, consideration should
be given to the non-healthcare related burden such as
the loss of labour productivity for the caregiver. Through
an increased understanding of the patient journey and
burden of illness, suitable resources and support for pa-
tients and their families can be identified.
This survey aimed to support the recognition of the
early symptoms of MPS VII by determining the pathway
to diagnosis, to increase understanding of the burden of
illness on patients, caregivers and healthcare resources
and to determine the support that is needed by individ-
uals with MPS VII and their families.
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Methods
Study design and patient selection
The patient organisations and/or specialist clinicians in
25 European countries were approached to see if they
were aware of any MPS VII patients. Patients and their
parents/caregivers were invited to take part in the study
by their local patient organisation or specialist clinician.
The survey was also advertised in the MPS Society UK
magazine and on their social media accounts.
Inclusion criteria
Individuals or their parents/caregivers with MPS VII, liv-
ing in Europe, were eligible to take part. In addition, the
responder had to be ≥18 years, able to complete the ques-
tionnaire and to provide informed consent to participate.
Assessments
The specifically designed questionnaire consisted of 59
questions arranged into the following sections: Person
with MPS VII and their family, path to diagnosis, sup-
port for physical needs, support for medical needs, sup-
port for learning and behavioural needs and other
support needed. The preferred method of completion
was via face to face or telephone interview with a patient
organisation that is local to the family. Where this was
not possible, the option to fill the questionnaire out by
post or e-mail was offered. Questionnaires were com-
pleted between 30 November 2017 and 31 March 2018.
Results
Demographics
A total of 18 patients were identified across 6 European
countries. The parents/caregivers of 13 of these patients
consented to take part in our study. One parent had two
children with MPS VII, giving a total of 12 respondents.
Five questionnaires were completed by telephone inter-
view with the patient’s local patient organisation. Two
were completed by the parent/caregiver with the help of
their specialist clinician and the remaining six were
completed by the parent/caregiver via post/e-mail.
The country of residence for patients were Germany
(n = 2), Spain (n = 3), The Netherlands (n = 2) and Turkey
(n = 6). The mean age of patients was 17.1 years (range 3.5
to 34 years). Five patients were currently receiving regular
ERT and two patients had received a HSCT.
Diagnosis in the presence or absence of NIHF
A diagnosis of NIHF was made in 38.5% of patients (5
out of 13), four patients before birth and one at birth or
shortly after. Of the patients that presented with NIHF
this led to testing and subsequent diagnosis of MPS VII
in all but one patient. Patients with NIHF were generally
diagnosed with MPS VII at an earlier age (mean 1.9
years, median 0.3 years, range 0.2 to 6 years, n = 5) than
those without NIHF (mean 6.1 years, median 6.0 years,
range 1.9 to 14 years, n = 7). For one individual diagnosed
at birth, the presence or absence of NIHF was unknown
by the responder. They noted that hospital investigations
were undertaken due to the coarse facial features of the
child. In those patients that did not present with NIHF
(n = 7), the mean age when symptoms began was 1.4 years
(median 0.3 years, range 0.1 to 5 years).
Pathway to diagnosis where testing for MPS VII was not
prompted by NIHF
For patients whose testing for MPS VII was not prompted
by the presence of NIHF, respondents were asked to de-
scribe the symptoms that were present before diagnosis,
who they consulted about symptoms and whether they had
received any other diagnoses (no NIHF (n = 7), NIHF
present (n = 1), NIHF status unknown (n = 1)). The most
common symptoms before diagnosis were coarse features,
hernias, sleep disturbance, recurrent ear infections, enlarged
liver and/or spleen, thick hair/eyebrows and large head
(Fig. 1). In those diagnosed over the age of two years (n =
7), delayed walking, speech and learning were common, oc-
curring in 42.9% (3/7), 57.1% (4/7) and 57.1% (4/7), respect-
ively. Loss of previously acquired walking ability, speech
and learning prior to diagnosis was reported for 25.0% (2/
8), 12.5% (1/8) and 12.5% (1/8) patients respectively.
Respondents were asked at what age the pre-diagnosis
symptoms first appeared. Five respondents also gave us
information on the appearance of symptoms after diag-
nosis and these are also reported in Fig. 2 to illustrate
the later manifestations of disease. The earliest symp-
toms, appearing at a median age of under one year, were
large head, sleep disturbance and hernia. Between the
median ages of one and two years, recurrent respiratory
infections, unusual eating habits, noisy breathing, snor-
ing and recurrent ear infections were noted. By three
years of age difficulty with toilet training, chronic nasal
discharge and hearing problems were present. Children
had recurrent constipation, coarse facial features, thick
hair and eyebrows and an enlarged liver and/or spleen
before their fourth birthday (Fig. 2).
In most cases, patients were seen by more than one
healthcare professional before their final diagnosis (mean
5.3 professionals), most commonly a hospital paediatri-
cian (Fig. 3). Prior to the diagnosis of MPS VII, 25% (2/
8) were diagnosed with autistic spectrum disorder (ASD)
and 25% (2/8) with Perthes disease. One patient was di-
agnosed with attention deficit hyperactivity disorder
(ADHD) and another with developmental delay.
The most common symptoms that lead to a suspicion
of MPS were an enlarged liver and/or spleen (66.7%, 6/
9), coarse facial features and thick hair/eyebrows (both
55.6%, 5/9). These features were not reported by par-
ents/caregivers until a median age of at least three years,
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although some did present at an earlier age (Fig. 2). Joint
stiffness or pain raised a suspicion of MPS VII in 44.4%
of patients (4/9). This symptom was reported as occur-
ring at a median age of 6.1 years (range 6 to 25 years).
Delayed speech was another symptom leading to a suspi-
cion of MPS VII in one third of patients (3/9). In one
patient, MPS was not suspected although their GAGs
were mildly elevated. Whole exome sequencing was per-
formed due to their delayed cognitive development and
identified the presence of MPS VII. This led to testing of
their sibling who was also found to have MPS VII.
Receiving a diagnosis
The diagnosis of MPS VII was made by a metabolic spe-
cialist consultant or a paediatrician specialising in meta-
bolic diseases in most cases (61.5%, 8/13). The remainder
were diagnosed by a geneticist (15.4%, 2/13), neurologist
(15.4%, 2/13) or a paediatrician (7.7%, 1/13).
Burden of illness
Patient burden
Overall, 61.5% (8/13) of patients were able to walk un-
aided, including two aged over 25 years. Four patients
(30.8%, 4/13) were described as having lost walking abil-
ity previously acquired.
Use of walking aids was seen in 15.4% (2/13) of pa-
tients and 23.1% (3/13) required a wheelchair. The youn-
gest patients to require walking aids or a wheelchair
were in the age range of 16—20 years.
While 38.5% (5/13) of patients had age appropriate
speech, almost half (46.2%, 6/13) had delayed speech de-
velopment. In two of the adult patients (aged over 20
years) there was some deterioration of the speech that
Fig. 1 Symptoms present before diagnosis in patients not tested for MPS VII due to the presence of NIHF (n = 8*). This was a multiple-choice
question. Respondents gave details of other symptoms for three patients: one patient with scoliosis, one patient with severe scoliosis, club foot
and hip dislocation and one patient with cleft palate. *Symptoms for the patient diagnosed at birth in whom the NIHF status was unknown were
not recorded by the respondent
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Fig. 2 Age when symptoms first occurred in patients not tested for MPS VII due to the presence of NIHF (n = 8*). *Symptoms for the patient
diagnosed at birth in whom the NIHF status was unknown were not recorded by the respondent. Respondents were asked to record the age of onset
of pre-diagnosis symptoms only. However, five respondents recorded the age of onset for some symptoms as occurring after the age of diagnosis
Fig. 3 Healthcare professionals consulted before diagnosis of MPS VII by patients not tested for MPS VII due to the presence of NIHF (n = 9). This
was a multiple-choice question, with the option to list any other healthcare professionals seen. Details of other healthcare professionals seen
were noted for three patients: one patient was seen by a neurologist, traumatologist, psychologist, doctor of internal medicine and
endocrinologist, one patient saw an orthopaedic doctor and one patient consulted a homeopath. ENT: ears, nose and throat
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had previously been acquired. Six patients (6/12) spoke
in short sentences, 16.7% (2/12) of patients could only
use single words to communicate but could also use
signs and hand signals.
Two patients (2/13) were described as having normal
cognitive development for their age (one of these
patients had received a HSCT). However, the majority of
patients were described as having delayed cognitive
development (69.2%, 9/13), while 15.4% (2/13) had lost
some cognitive skills that had previously been acquired.
Most patients (92.3%, 12/13) experienced joint stiff-
ness or pain and thick hair and eyebrows (69.2%, 9/13).
Coarse facial features (61.5%, 8/13) were common. Over
half (53.8%, 7/13) were experiencing dental problems
and sleep disturbance. Corneal clouding, enlarged liver
and/or spleen and heart problems occurred in (46.2%, 6/
13) of patients (Fig. 4).
Whilst 30.8% (4/13) of patients had no behavioural is-
sues, most patients had some degree of behavioural symp-
toms such as short attention span, challenging behaviour
or repetitive behaviour (all 46.2%, 6/13), hyperactivity
(30.8%, 4/13) and no awareness of danger (7.7%, 1/13).
Caregiver burden
When asked what the most difficult aspects of the disease
to manage were, the most frequent answers related to be-
haviour and mobility. Just over 30% (4/13) of patients did
not need any help with daily activities; but over half (53.8%,
7/13) required assistance with having a bath or shower and
one third (30.8%, 4/13) required assistance with using the
toilet, getting dressed, moving around outside and help dur-
ing the night (Fig. 5). To adjust to issues with mobility, two
families had to move to a more suitable house, one family
installed a lift and two families said they had to provide
Fig. 4 Current symptoms (n = 13). This was a multiple-choice question. Respondents gave details of other symptoms for four patients: one
patient previously had difficulty with toilet training, one patient had severe scoliosis, short stature, a small and rigid thorax, hip dislocation and
genu valgum, one patient had knee pain, back pain, side (spleen) pain and an enlarged spleen
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other home adaptations for their child. Most patients were
being cared for by their family, either by one (53.8%, 7/13)
or two (30.8%, 4/13) parents, although 15.4% (2/13) were
attended to by professional caregivers. Commonly, one par-
ent either reduced their working hours (46.2%, 6/13) or
stopped working (30.8%, 4/13) to care for their child. Over
half (53.8%, 7/13) of patients have government provided fi-
nancial support for care.
Medical needs
Most of the patients (84.6%, 11/13) had undergone at least
one surgery, the most common was insertion of ear T-
tubes or grommets. The other types of surgery or proce-
dures undergone by patients were orthopaedic surgery,
tonsillectomy, removal of adenoids, dental treatment
under general anaesthesia and insertion of a shunt to treat
hydrocephalus. The frequency and mean age at which pa-
tients had surgery is displayed in Table 1. Five patients
were currently receiving ERT and most were on some
other type of regular medication, the most common was
for the heart (23.1%, 3/13), but only one patient was taking
painkillers and one other was taking anti-inflammatories.
More than half (58.3%, 7/12) were receiving physiotherapy
and two patients were receiving animal therapy (hip-
potherapy). One third of patients (4/12) received no sup-
portive therapies. These four patients were from Turkey
and no requirement for additional therapies were identi-
fied by the parents/caregivers.
Overall, patients would attend multiple appointments in
a typical year (Fig. 6) with the total number of visits in a
year ranging from 4 to 28 (mean 12.7, n = 12). Around
30% (4/13) of patients had been hospitalised for respira-
tory issues with patients staying in hospital for up to 10
days, although none had recorded time in intensive care.
Learning and behavioural needs
Learning support was generally available where needed,
although one parent/caregiver in Germany did not have
access to support for their child’s learning.
Children most often started their education in a school
for children of all abilities, with 41.7% (5/12) attending
at least one specialist school for children with learning
Fig. 5 Help needed with daily activities (n = 13). Other help that was noted by respondents included family counselling, one-to-one to help in
connection with their learning difficulties (to take pressure off mother), support in the morning to encourage independence, and assistance
with wheelchair
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difficulties during their education. The mean age of chil-
dren starting at a specialist school for children with
learning difficulties was 7.6 years (range 1 to 14 years).
The most commonly provided school assistance was a
specialist teacher, received by over half the patients at
their first and second educational establishments (55.6%
(5/9) and 60.0% (6/10) respectively). While no individ-
uals received one-to-one support at their first educa-
tional establishment, 40% (4/10) received it at their
second school. Professional support at school included
that provided by physiotherapists, speech and language
therapists, educational psychologists and special educa-
tional needs co-ordinators, received by 72.7% (8/11),
54.5% (6/11), 72.7% (8/11) and 54.5% (6/11) of patients
respectively, at one or more of their educational estab-
lishments attended to date.
Sixty-nine percent (9/13) of patients had some behavioural
issues. Most (67%, 6/9) were receiving support for their be-
havioural needs through their school. No respondents re-
ported that this type of support was unavailable if needed.
Support needs
After diagnosis, the information about the disease that
was given to patients and their caregivers was variable
with most receiving some information from a doctor, al-
though two parents/caregivers received no information at
all. Only respondents in Germany and The Netherlands
were provided with information about a patient organisa-
tion and only one individual received any written informa-
tion about the disease. Six out of 12 respondents (from
Turkey (n = 4), Germany (n = 1) and Spain (n = 1)) were
not offered genetic counselling. The individuals with MPS
VII in these cases were diagnosed 15 or more years ago in
Germany and Spain and between 3 and 14 years ago in
Turkey. All but one of the respondents not offered genetic
counselling would like access to this service.
When asked about the support that caregivers received
for their child’s additional needs, only half (6/12) had ac-
cess to support for their child’s mobility. Three respon-
dents, from Turkey and Germany, did not have access to
services to support home adaptations. Social care sup-
port such as social assistance and hospice/respite care
was unavailable to 18% (2/11) of respondents, they were
also residents of Turkey and Germany. Just over half
Table 1 Frequency and mean age of surgical procedures
(n = 13)
Surgery % patients
(n/N)
Mean age
(years)
Insertion of ear T-tubes or grommets 46.2, (6/13) 3.5
Removal of tonsils 30.8, (4/13) 3.1
Orthopaedic surgery (e.g. hip replacement) 30.8, (4/13) 11.5
Removal of adenoids 23.1, (3/13) 5.8
Dental treatment under general anaesthesia 23.1, (3/13) 9.0
Insertion of a shunt to treat hydrocephalus 7.7, (1/13) 2.5
Fig. 6 Number of medical appointments in a typical year (n = 12). Patients attend multiple appointments in a typical year and see a variety of
medical professionals. This figure does not include visits made for a clinical trial or any additional comments that were listed by respondents in
the questionnaire. These comments included ‘There are routine checks every six months’, ‘cardiologist once a year’, and ‘complete check-up
when needed’. ENT: ears, nose and throat
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(53.8%, 7/13) said they received government funded fi-
nancial support for the care of their child.
Discussion
This European survey is the first of its kind to describe
MPS VII diagnosis capturing the patient and caregiver ex-
perience, their pathway to the final diagnosis of MPS VII,
the burden of illness and the support that patients and
their families need. Early diagnosis and appropriate treat-
ment is likely to improve quality of life but for patients
that do not present with NIHF, diagnosis can take several
years. Early symptoms can be non-specific with variable
clinical presentations and severity that can be mistaken
for other conditions thus impeding rapid and accurate
diagnosis. A key finding of this survey is that the symp-
toms that are most likely to raise suspicion of MPS VII, in
the absence of NIHF, typically do not appear until age
three or older. Enhancing disease awareness among
healthcare professionals is paramount to ensure that the
earliest symptoms can be identified and a suspicion of an
MPS disorder raised for appropriate referral and further
testing. Newer diagnostic techniques like whole exome se-
quencing can also help to identify MPS VII [24], as was
the case for two patients in our study. This technique is
particularly useful for patients in whom a genetic diagno-
sis is suspected, but the phenotype does not resemble a
known syndrome or when biochemical and genetic testing
have failed to arrive at a diagnosis [24].
In our survey, NIHF at birth was reported in approxi-
mately 40% of patients, a similar proportion to that re-
ported in the literature [1], which is why it is important
to include MPS VII in the differential diagnosis of NIHF.
However, presentation of NIHF prenatally or at birth
can result from a large number of different pathologies
and identifying the cause depends on the thoroughness
of testing to establish a diagnosis [25]. In a review of the
literature to evaluate the incidence of lysosomal storage
diseases in NIHF, the incidence varied between 1.3 to
5% of cases although of these cases MPS VII was the
most common [26, 27]. MPS VII may account for as
many as a quarter of the lysosomal storage disorders
that present as NIHF [28]. Gimovsky et al. report that in
18–30% of NIHF cases the initial assessment revealed no
probable cause but further testing resulted in a diagnosis
of a lysosomal storage disorder in 17.4% of cases [26].
This highlights the need for comprehensive testing for
lysosomal storage disorders following the initial assess-
ment where NIHF is found to be idiopathic.
From this survey it was clear that even after diagnosis
parents and caregivers are not always given adequate in-
formation about the condition. The information avail-
able at diagnosis varied by country, with some families
in Spain and Turkey being given no information at all.
This may be because medical professionals are not aware
of the information that is available due to the rarity of
the disease. Parents and caregivers find there is a lack of
information about MPS VII, disease progression and
treatment, highlighting both the need for increased
awareness of the resources currently available and fur-
ther research into the natural history and effects of treat-
ment of MPS VII. A global, prospective, multicentre,
longitudinal study called the Disease Monitoring
Programme is currently underway. It is designed to
characterise MPS VII disease presentation and progres-
sion over time in patients treated and not treated with
ERT, and assess long-term effectiveness and safety of
ERT, including hypersensitivity reactions and immuno-
genicity, in patients with MPS VII [29]. Clearly there is a
need for such initiatives and the facility for patients, cli-
nicians and researchers to record and share data on this
ultra-rare disease.
The survey also highlights the need for greater access
to genetic counselling with respondents in Turkey hav-
ing the least access. Genetic counselling can help parents
understand the medical implications, provide support
and advice and an opportunity to discuss implications if
further children are planned.
MPS VII imposes significant burden on patients and
their families. Assessment of functional abilities in MPS
patients show they are much lower than age-matched
controls with an average score in the severe dependence
range [23]. Parents/caregivers in our study identified is-
sues with mobility as one of the most difficult aspects of
the disease to manage. While the majority of patients
(61.5%, 8/13) in our study could walk unaided, some
adult patients needed walking aids or wheelchairs and
most patients (69.2%, 9/13) needed help with daily activ-
ities. Péntek et al., reported that non-professional care-
givers of patients with MPS spend a mean of 51 h per
week giving informal care [23]. It is therefore not sur-
prising that for 76.9% (10/13) of patients in this study,
one parent/caregiver had reduced their working hours
or stopped working. MPS VII can place a considerable
financial burden on families, including loss of earnings
and the need for adaptations to the home.
Parents/caregivers in this study found behavioural is-
sues difficult to manage and reported behavioural diffi-
culties in 69.2% (9/13) of patients. Previous studies of
caregiver burden in MPS diseases have also reported be-
havioural symptoms to be among the most challenging
for families along with sleep disturbance and communi-
cation difficulties [30, 31]. In our study, 53.8% (7/13) of
patients currently had sleep disturbance, 30.8% (4/13)
needed help during the night and only 50.0% (6/12) were
described as speaking in an age appropriate manner.
Dealing with these symptoms and the physical burden of
daily care, can have a cumulative impact and impose sig-
nificant psychological stress on caregivers [31].
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While studies have shown that the quality of life of
patients with MPS diseases and their caregivers is
negatively impacted, there is a lack of specific measures
for this patient population [32, 33]. The impact of MPS
diseases on the family has been shown to be similar to that
for other paediatric outpatients with chronic illnesses and
caregiver burden increases with disease progression and
loss of mobility [32].
Access to social support for mobility, care and housing
was not necessarily available to all with some parents
saying they would like more support. This survey and a
previous survey of MPS patients and carers noted that
health and social care varies across countries [23]. It is
important not to under-estimate the importance of in-
formal care and its impact on quality of life, both for pa-
tients and caregivers.
The costs to health services associated with MPS VII
include treatment with disease modifying and supportive
therapies, multiple medical appointments, hospitalisa-
tions and surgeries. The proportion of non-healthcare
related formal costs, including the cost of professional
caregivers, non-healthcare transport and social services
should also be considered. Péntek et al. report that the
majority of healthcare costs related to MPS are attrib-
uted to drugs, medical visits, hospitalisations and non-
healthcare formal and informal care [23].
Many of the patients in our survey needed support in
education. Generally, caregivers had access to additional
support with learning and behavioural issues at school
and/or via attendance at a specialist school for children
with additional needs.
The main limitation of this study has been the small
sample size, resulting from the extreme rarity of MPS
VII. In addition, some respondents completing the ques-
tionnaire via post or e-mail skipped questions, leading to
missing data. The heterogeneous population of patients
and small numbers have limited any possibility of carry-
ing out a rigorous statistical analysis of the data and
resulted in a purely observational study. Furthermore,
the most severe cases of MPS VII are not represented by
this study as some MPS VII will go undiagnosed due to
stillbirth, or death in the early weeks of life. As we only
reported on patients who survived, the overall propor-
tion of MPS VII patients who present with NIHF is
likely to be higher than reported in our study.
Conclusions
In this study we report that the pathway to a diagnosis
of MPS VII can be lengthy even after the first symp-
toms have appeared and particularly where patients do
not present with NIHF. Greater awareness of the early
signs of MPS VII is needed and more understanding of
the disease.
Parents and caregivers are not always provided with
adequate information about the condition and may not
be offered genetic counselling. Greater awareness of the
resources available from patient organisations and spe-
cialist centres may be needed in some areas of Europe to
support the clinicians giving a diagnosis of MPS VII and
managing these patients.
This study highlights many aspects of disease burden
for patients and their caregivers including the levels of
care, housing, medical and educational support that are
required. The burden of illness not only affects quality
of life for patients but also for their caregivers, and there
is an associated financial burden on families, healthcare,
social and educational resources. Further studies are
warranted to understand more fully the burden of illness
and socio-economic impact of MPS VII in European and
other countries around the world.
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